Provided is a fluorine atom-containing compound represented by formula (1) below
(In the formula, Z represents a predetermined divalent group, each Ar independently represents a predetermined aromatic ring-containing group, and each Ar
F
independently represents a predetermined fluorine atom-containing aryl group).
Fluorine deshielding in the proximity of a methyl group. An experimental and theoretical study
作者:Gordon W. Gribble、Daniel J. Keavy、Erik R. Olson、Ian D. Rae、Alfred Staffa、Tomas E. Herr、Marta B. Ferraro、Rubén H. Contreras
DOI:10.1002/mrc.1260290504
日期:1991.5
19F chemicalshifts are reported for a series of alkyl‐substituted fluoronaphthalenes and related compounds that exhibit steric crowding around the fluorine atom due to the proximity of methyl groups. Comparisons of these chemicalshifts with others measured in similar compounds but without the corresponding methyl groups show that this crowding effect produces a large low‐field shift of the 19F signal
Reinterpretation of long-range 1H-19F spin—spin coupling in 1,4-dihydro-1,4-epoxynaphthalenes and related systems
作者:Gordon W. Gribble、William J. Kelly
DOI:10.1016/s0040-4039(01)92936-3
日期:1981.1
The long-range 1H-19F coupling reported earlier for the bridgehead proton(s) in 1,4-dihydro-1,4-epoxynaphthalenes (e.g., ) is shown unequivocally to involve the distal fluorine by a five-bond zig-zag coupling pathway.
较早前报道的1,4-二氢-1,4-环氧萘(例如)中桥头质子的远程1 H - 19 F偶合清楚地表明是通过五键Zig- zag耦合途径。
HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME
申请人:Samsung Display Co., Ltd.
公开号:US20190131535A1
公开(公告)日:2019-05-02
A heterocyclic compound and an organic light-emitting device including the same are provided. The organic light-emitting device includes: a first electrode; a second electrode facing the first electrode; and an organic layer disposed between the first electrode and the second electrode, where the organic layer may include an emission layer and at least one of the heterocyclic compound described above.
A novel class of compounds as KRas G12C inhibitors. Also disclosed are pharmaceutical compositions of the KRas G12C inhibitors and methods of treating KRas G12C associated diseases.